A
ArginateCare

What the PDA Research Actually Shows

By ArginateCare Editorial TeamPublished July 22, 2026

Medical-review status: A licensed medical reviewer has not yet been assigned to this page. Until one is, the page is published as an editorial draft and is not presented as medically reviewed. See our medical review policy.

Medical disclaimer: This article is educational and is not medical advice, diagnosis, or treatment. Neither Pentadeca Arginate nor BPC-157 is an FDA-approved drug. Do not start, stop, or change any treatment based on this page. Always consult a licensed U.S. healthcare provider about your situation.

Quick answer

We found no peer-reviewed studies of Pentadeca Arginate itself. The research people point to is about BPC-157 and is largely preclinical. Reviews conclude the evidence is early and cannot support routine human use.

Evidence summary:Preclinical evidence

No PDA-specific studies; the related BPC-157 evidence is mostly animal and laboratory work. (Animal or laboratory findings only. Does not prove effects in humans.)

Direct PDA research

No direct PDA evidence

No direct evidence identifiedNo direct clinical evidence for Pentadeca Arginate was identified in the reviewed literature. The research below concerns BPC-157 or related preclinical models and should not be interpreted as proof of PDA safety or effectiveness.

The BPC-157 evidence base

Preclinical evidenceBPC-157 has been studied mainly in animals and cell cultures, with reported effects in tendon and gastrointestinal healing models.[1],[2],[3]

Preclinical evidenceA systematic review of BPC-157 in orthopaedic sports medicine and a recent narrative review both conclude the human evidence is minimal and the risk–benefit picture is unresolved.[4],[5]

The evidence gaps that matter most

  • No human trials of PDA for any condition.
  • No published human pharmacology for the arginate salt form.
  • No long-term human safety data.
  • Reliance on animal studies that frequently do not translate to people.

Frequently asked questions

Are there human studies on PDA?

We found none. The available research is on BPC-157 and is largely preclinical.

References

5 peer-reviewed journal sources and 1 additional authoritative reference. Every reference supports a specific statement above.

  1. [1] Gwyer D, Wragg NM, Wilson SL (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2):153–159. View source Peer-reviewed journal
  2. [2] Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JS (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3):774–780. View source Peer-reviewed journal
  3. [3] Sikirić P, Seiwerth S, Rucman R, et al. (2011). Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 17(16):1612–1632. View source Peer-reviewed journal
  4. [4] Vasireddi N, Hahamyan H, Salata MJ, et al. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal (SAGE), Systematic review. View source Peer-reviewed journal
  5. [5] Current Reviews in Musculoskeletal Medicine (2025). Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine, Narrative review. View source Peer-reviewed journal
  6. [6] Operation Supplement Safety (U.S. Department of Defense) (2024). BPC-157: a prohibited peptide and an unapproved drug found in health and wellness products. OPSS.org (DoD), U.S. government consumer-safety advisory. View source Government / regulatory

Continue reading

Back to the complete PDA guidePDA safety informationWhat the PDA research showsTendonitis researchPeptic ulcer researchSports-injury recoveryPDA vs BPC-157 research